GIPR and Obesity: The Study of Tirzepatide in Participants with Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide reduced the risk of worsening HF compared with placebo in patients with obesity-related HFpEF, while reducing HF symptom severity and improving exercise tolerance16.